Real time stability and viability prediction of the anticancer BCG after lyophilization

Abstract To test if trehalose could be a better cryoprotectant for BCG than the usually used lactose and predict viability of BCG during shelf-life, BCG was suspended into three stabilizer systems containing 15% w/v trehalose, trehalose–gelatin mixture (in ratio, 30:1 w/w) or lactose. Each formula was lyophilized and several quality parameters were tested before and after lyophilization including sterility, safety, viability, morphology and moisture content. Samples of lyophilized formulae were tested for their reconstitution time and others were charged to stability chambers at 5 °C for the performance of real time study. Shelf-life of each formula was estimated and correlation between moisture content and loss in viability was established at each time interval of the real time stability study. Sterility, safety and morphology were retained after lyophilization. Just after lyophilization, minute diminish in viability was observed in the presence of each stabilizer (0.02–0.05%). There was no significant difference in reconstitution time of the three lyophilized formulae. Lactose BCG had the highest shelf-life among the used cryoprotectants during the real time stability studies. Also, moisture content was highly correlated to viability with correlation coefficient ranged between 0.97 and 0.99 and so, the former could be used for prediction of viability throughout the vaccine shelf-life.

[1]  M. Rafiee-Tehrani,et al.  Lyophilized insulin nanoparticles prepared from quaternized N-aryl derivatives of chitosan as a new strategy for oral delivery of insulin: in vitro, ex vivo and in vivo characterizations , 2014, Drug development and industrial pharmacy.

[2]  A. Elshafeey,et al.  Design of lipotomes as a novel dual functioning nanocarrier for bioavailability enhancement of lacidipine: in-vitro and in-vivo characterization. , 2014, International journal of pharmaceutics.

[3]  Y. Boum,et al.  Lowenstein-Jensen Selective Medium for Reducing Contamination in Mycobacterium tuberculosis Culture , 2014, Journal of Clinical Microbiology.

[4]  Nastaran Nafissi-varcheh,et al.  Challenges to Improve the Stability and Efficacy of an Intravesical BCG Product , 2014, Iranian journal of pharmaceutical research : IJPR.

[5]  J. Witjes,et al.  Current intravesical therapy for non-muscle invasive bladder cancer , 2013, Expert opinion on biological therapy.

[6]  T. Dziubla,et al.  Optimization of the lyophilization process for long-term stability of solid–lipid nanoparticles , 2012, Drug development and industrial pharmacy.

[7]  D. Globe,et al.  Surveillance and Treatment of Non-Muscle-Invasive Bladder Cancer in the USA , 2012, Advances in urology.

[8]  E. Tsao,et al.  Improved formulation and lyophilization cycle for rBCG vaccine. , 2011, Vaccine.

[9]  Peter Langguth,et al.  Role of continuous moisture profile monitoring by inline NIR spectroscopy during fluid bed granulation of an Enalapril formulation , 2011, Drug development and industrial pharmacy.

[10]  I. Knezevic,et al.  WHO Informal Consultation on standardization and evaluation of BCG vaccines Geneva, Switzerland 22-23 September 2009. , 2010, Vaccine.

[11]  N. Jain,et al.  Trehalose and Protein Stability , 2010, Current protocols in protein science.

[12]  S. Shariat,et al.  Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review. , 2009, International braz j urol : official journal of the Brazilian Society of Urology.

[13]  I. Knezevic,et al.  WHO/KFDA workshop on stability evaluation of vaccines, Seoul, Korea, 23-25 April 2008. , 2009, Biologicals (Print).

[14]  T. Schofield.  Vaccine stability study design and analysis to support product licensure. , 2009, Biologicals : journal of the International Association of Biological Standardization.

[15]  P. White,et al.  Preservation of micro-organisms by drying; a review. , 2006, Journal of microbiological methods.

[16]  Xiaolin Tang,et al.  Design of Freeze-Drying Processes for Pharmaceuticals: Practical Advice , 2004, Pharmaceutical Research.

[17]  R. Bhat,et al.  Why Is Trehalose an Exceptional Protein Stabilizer? , 2003, Journal of Biological Chemistry.

[18]  A. Elbein,et al.  New insights on trehalose: a multifunctional molecule. , 2003, Glycobiology.

[19]  M. Behr.  BCG--different strains, different vaccines? , 2002, The Lancet. Infectious diseases.

[20]  A. E. Oliver,et al.  The trehalose myth revisited: introduction to a symposium on stabilization of cells in the dry state. , 2001, Cryobiology.

[21]  J. Argüelles,et al.  Physiological roles of trehalose in bacteria and yeasts: a comparative analysis , 2000, Archives of Microbiology.

[22]  W. Wang,et al.  Lyophilization and development of solid protein pharmaceuticals. , 2000, International journal of pharmaceutics.

[23]  Stephen F. Perry.  Freeze-drying and cryopreservation of bacteria , 1998, Molecular biotechnology.

[24]  D S Reid,et al.  Is trehalose special for preserving dry biomaterials? , 1996, Biophysical journal.

[25]  J H Crowe,et al.  Trehalose and sucrose protect both membranes and proteins in intact bacteria during drying , 1995, Applied and environmental microbiology.

[26]  G. Stacey,et al.  Cryopreservation and Freeze-Drying Protocols , 1995, Methods in Molecular Biology™.

[27]  J. Crowe,et al.  Preservation of freeze-dried liposomes by trehalose. , 1985, Archives of biochemistry and biophysics.

[28]  N. A. Williams,et al.  The lyophilization of pharmaceuticals: a literature review. , 1984, Journal of parenteral science and technology : a publication of the Parenteral Drug Association.

[29]  H. Passing,et al.  Standardization of BCG vaccine by bacterial weight: variables influencing the uniformity of the product. , 1981, Journal of Biological Standardization.

[30]  P. Muggleton,et al.  Evaluation of the stability of dried BCG vaccine. , 1972, Tubercle.

[31]  T. Araki,et al.  Effect of residual moisture content on the survival of freeze-dried bacteria during storage under various conditions. , 1966, Cryobiology.

[32]  P. Muggleton,et al.  Preparation and Properties of a Freeze-dried B.C.G. Vaccine of Increased Stability , 1962, British medical journal.

[33]  H. Meryman,et al.  PRINCIPLES OF FREEZE‐DRYING , 1960, Annals of the New York Academy of Sciences.

[34]  P. Muggleton,et al.  Freeze-dried B.C.G. Vaccine , 1956, British medical journal.

[35]  K. Goodner,et al.  Studies on the Stability of Lyophilized BCG Vaccine *† , 1953, The Yale Journal of Biology and Medicine.

[36]  H. Herr,et al.  History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. , 2008, The Journal of urology.

[37]  J. Crowe.  Trehalose as a "chemical chaperone": fact and fantasy. , 2007, Advances in experimental medicine and biology.

[38]  J. Crowe.  Trehalose As a “Chemical Chaperone” , 2007 .

[39]  K. Ranganathan.  The Present Position of Freeze-Dried BCG Vaccine , 2005 .

[40]  P. Castle.  European Pharmacopoeia (EP), USDA and MAFF standards--will they ever be harmonised under the VICH umbrella? , 2005, Developments in Biologicals.

[41]  International Conference on Harmonisation; evaluation of stability data; availability. Notice. , 2004, Federal register.

[42]  International Conference on Harmonisation; Stability Data Package for Registration Applications in Climatic Zones III and IV; Stability Testing of New Drug Substances and Products; availability. Notice. , 2003, Federal register.

[43]  Steven L Nail,et al.  Fundamentals of freeze-drying. , 2002, Pharmaceutical biotechnology.

[44]  International Conference on Harmonisation; guidance on Q1A stability testing of new drug substances and products; availability. Notice. , 2001, Federal register.

[45]  I. N. Brown,et al.  Three pathways for trehalose biosynthesis in mycobacteria. , 2000, Microbiology.

[46]  Day Jg,et al.  Cryopreservation and freeze-drying protocols. Introduction. , 1995 .

[47]  J. Gibson,et al.  Quality control of BCG vaccine by WHO: a review of factors that may influence vaccine effectiveness and safety. , 1990, Bulletin of the World Health Organization.

[48]  B. Mackey.  Lethal and sublethal effects of refrigeration, freezing and freeze-drying on micro-organisms. , 1984, Society for Applied Bacteriology symposium series.

[49]  Mackey Bm.  Lethal and sublethal effects of refrigeration, freezing and freeze-drying on micro-organisms , 1984 .

[50]  P. Lagrange,et al.  Viability, heat stability and immunogenicity of four BCG vaccines prepared from four different BCG strains. , 1983, Annales d'immunologie.

[51]  Who recommendations for BCG. , 1976, La Clinica pediatrica.

[52]  Y. Obayashi,et al.  Effect of adjuvant on preservability of dried BCG vaccine at 37 degrees C. , 1956, Bulletin of the World Health Organization.

[53]  Y. Obayashi.  Dried BCG vaccine. , 1955, Monograph series. World Health Organization.